Evaluation and Management of Thyrotropin-Secreting Pituitary Adenomas

References

• Jailer JW , HolubDA. Remission of Graves’ disease following radiotherapy of a pituitary neoplasm. Am. J. Med.28, 497–500 (1960).
   PubMed Web of Science ®Google Scholar
• Hamilton CR Jr , AdamsLC, MaloofF. Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. N. Engl. J. Med.283(20), 1077–1080 (1970).
   PubMed Web of Science ®Google Scholar
• Daly AF , RixhonM, AdamC, DempegiotiA, TichomirowaMA, BeckersA. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab.91(12), 4769–4775 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez A , KaravitakiN, WassJA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxford)72(3), 377–382 (2010).
   PubMed Web of Science ®Google Scholar
• Onnestam L , BerinderK, BurmanPet al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J. Clin. Endocrinol. Metab.98(2), 626–635 (2013).
   PubMed Web of Science ®Google Scholar
• Raappana A , KoivukangasJ, EbelingT, PirilaT. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J. Clin. Endocrinol. Metab.95(9), 4268–4275 (2010).
   PubMed Web of Science ®Google Scholar
• Brucker-Davis F , OldfieldEH, SkarulisMC, DoppmanJL, WeintraubBD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J. Clin. Endocrinol. Metab.84(2), 476–486 (1999).
   PubMed Web of Science ®Google Scholar
• Clarke MJ , EricksonD, CastroMR, AtkinsonJL. Thyroid-stimulating hormone pituitary adenomas. J. Neurosurg.109(1), 17–22 (2008).
   PubMed Web of Science ®Google Scholar
• Socin HV , ChansonP, DelemerBet al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eu. J. Endocrinol.148(4), 433–442 (2003).
   PubMed Web of Science ®Google Scholar
• Tagami T , UsuiT, ShimatsuA. Aberrant expression of thyroid hormone receptor beta isoform cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J. Clin. Endocrinol. Metab.96(6), E948–E952 (1996).
   Google Scholar
• Furumoto H , YingH, ChandramouliGVet al. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol. Cell. Biol.25(1), 124–135 (2005).
   PubMed Web of Science ®Google Scholar
• Ando S , SarlisNJ, OldfieldEH, YenPM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J. Clin. Endocrinol. Metab.86(11), 5572–5576 (2001).
   PubMed Web of Science ®Google Scholar
• Lu C , WillinghamMC, FuruyaF, ChengSY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology149(7), 3339–3345 (2008).
   PubMed Web of Science ®Google Scholar
• Tannahill LA , VisserTJ, MccabeCJet al. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clin. Endocrinol. (Oxford)56(6), 735–743 (2002).
   PubMed Web of Science ®Google Scholar
• Umeoka K , SannoN, OsamuraRY, TeramotoA. Expression of GATA-2 in human pituitary adenomas. Mod. Pathol.15(1), 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Barlier A , VanbellinghenJF, DalyAFet al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.92(5), 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P , PersaniL, MannavolaD, CampiI. Pituitary tumours: TSH-secreting adenomas. Best Pract. Res. Clin. Endocrinol. Metab.23(5), 597–606 (2009).
   PubMed Web of Science ®Google Scholar
• Daly AF , TichomirowaMA, PetrossiansPet al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab.95(11), E373–E383 (2010).
   PubMed Web of Science ®Google Scholar
• Brown RL , MuzzafarT, WollmanR, WeissRE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur. J. Endocrinol.154(5), 639–643 (2006).
   PubMed Web of Science ®Google Scholar
• Lee W , CheungAS, FreilichR. TSH-secreting pituitary carcinoma with intrathecal drop metastases. Clin. Endocrinol. (Oxford)76(4), 604–606 (2012).
   PubMed Web of Science ®Google Scholar
• Tritos NA , EppakayalaS, SwearingenBet al. Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary16(3), 287–293 (2013).
   PubMed Web of Science ®Google Scholar
• Ness-Abramof R , IshayA, HarelGet al. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary10(3), 307–310 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu FS , TsaiWS, ChauT, ChenHH, ChenYC, LinSH. Thyrotropin-secreting pituitary adenoma presenting as hypokalemic periodic paralysis. Am. J. Med. Sci.325(1), 48–50 (2003).
   PubMed Web of Science ®Google Scholar
• Pappa T , PapanastasiouL, MarkouAet al. Thyrotoxic periodic paralysis as the first manifestation of a thyrotropin-secreting pituitary adenoma. Hormones (Athens)9(1), 82–86 (2010).
   PubMedGoogle Scholar
• Mcleod DS , WattersKF, CarpenterAD, LadensonPW, CooperDS, DingEL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J. Clin. Endocrinol. Metab.97(8), 2682–2692 (2012).
   PubMed Web of Science ®Google Scholar
• Unluturk U , SriphrapradangC, ErdoganMFet al. Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature. J. Clin. Endocrinol. Metab.98(6), 2210–2217 (2013).
   PubMed Web of Science ®Google Scholar
• Abs R , StevenaertA, BeckersA. Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause‐‐effect relationship. Eur. J. Endocrinol.131(4), 355–358 (1994).
   PubMed Web of Science ®Google Scholar
• Iskandar SB , SupitE, JordanRM, PeirisAN. Thyrotropin-secreting pituitary tumor and Hashimoto’s disease: a novel association. South. Med. J.96(9), 933–936 (2003).
   PubMed Web of Science ®Google Scholar
• Refetoff S , DumitrescuAM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract. Res. Clin. Endocrinol. Metab.21(2), 277–305 (2007).
   PubMed Web of Science ®Google Scholar
• Hall WA , LucianoMG, DoppmanJL, PatronasNJ, OldfieldEH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern. Med.120(10), 817–820 (1994).
   PubMed Web of Science ®Google Scholar
• Safer JD , ColanSD, FraserLM, WondisfordFE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid11(3), 281–291 (2001).
   PubMed Web of Science ®Google Scholar
• Sung JK , KimEM, NamSMet al. A TSH-secreting pituitary microadenoma diagnosed with inferior petrosal sinus sampling. Korean J. Med.76, 752–757 (2009).
   Google Scholar
• Cooper DS , WenigBM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid6, 337–343 (1996).
   PubMed Web of Science ®Google Scholar
• Pasquini E , Faustini-FustiniM, SciarrettaVet al. Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur. J. Endocrinol.148(2), 253–257 (2003).
   PubMed Web of Science ®Google Scholar
• Mannavola D , PersaniL, VannucchiGet al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin. Endocrinol. (Oxford)62(2), 176–181 (2005).
   PubMed Web of Science ®Google Scholar
• Watanabe K , KameyaT, YamauchiAet al. Thyrotropin-producing microadenoma associated with pituitary resistance to thyroid hormone. J. Clin. Endocrinol. Metab.76(4), 1025–1030 (1993).
   PubMed Web of Science ®Google Scholar
• Sanno N , TeramotoA, OsamuraRY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J. Neurosurg.93(2), 194–200 (2000).
   PubMed Web of Science ®Google Scholar
• Ezzat S , HorvathE, KovacsK, SmythHS, SingerW, AsaSL. Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr. Pathol.6(2), 125–134 (1995).
   PubMed Web of Science ®Google Scholar
• Losa M , GiovanelliM, PersaniL, MortiniP, FagliaG, Beck-PeccozP. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab.81(8), 3084–3090 (1996).
   PubMed Web of Science ®Google Scholar
• Macchia E , GasperiM, LombardiMet al. Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitaryadenomas: a single center experience. J. Endocrinol. Invest.32(9), 773–779 (2009).
   PubMed Web of Science ®Google Scholar
• Marucci G , Faustini-FustiniM, RighiAet al. Thyrotropin-secreting pituitarytumours: significance of “atypical adenomas” in a series of 10patients and association with Hashimoto thyroiditis as a cause of delay indiagnosis. J. Clin. Pathol.62(5), 455–459 (2009).
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P , PersaniL. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary5(2), 83–88 (2002).
   PubMedGoogle Scholar
• Caron P , ArlotS, BautersCet al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab.86(6), 2849–2853 (2001).
   PubMed Web of Science ®Google Scholar
• Kuhn JM , ArlotS, LefebvreHet al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J. Clin. Endocrinol. Metab.85(4), 1487–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Gatto F , BarbieriF, GattiMet al. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin. Endocrinol. (Oxford)76(3), 407–414 (2012).
   PubMed Web of Science ®Google Scholar
• Fliers E , Van FurthWR, BisschopPH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin. Endocrinol. (Oxford)77(5), 788–790 (2012).
   PubMed Web of Science ®Google Scholar